Moderna mRNA flu vaccine to get FDA panel review

Moderna's experimental mRNA flu vaccine (MFLUSIVA) will undergo FDA advisory panel review on June 18. This development follows the departure of former FDA head Marty Makary and signals a return to more stable regulatory processes for drug reviews.